78
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      scite_
       
      • Record: found
      • Abstract: found
      • Conference Proceedings: found
      Is Open Access

      Advancing Biobanking in Europe to Foster Diagnostics and Therapies Discovery & Development

      Published
      conference-abstract
      Bookmark

            Abstract

            Background/Objectives: BBMRI-ERIC is the European research infrastructure for biobanking and biomolecular resources. BBMRI has been granted ERIC-status (European Research Infrastructure Consortium) by the European Commission in 2013. Currently, 24 countries and the World Health Organisation’s International Agency for Research on Cancer constitute with its National Nodes and affiliated biobanks BBMRI-ERIC as one of the largest infrastructures in health and life sciences. BBMRI-ERIC’s mission is to facilitate access to sample, data, and biomolecular resources to enable high-quality research, particularly personalized medicine.

            Methods/Results: This is facilitated through services and advancements in the areas of Ethical, Legal and Societal Issues (ELSI), Quality Management (QM), Information Technology (IT), Biobank Development (BBD), Public Affairs (PA), Outreach, Education & Communications (OEC), and Finance- and Project Management (FPM). Hereby, BBMRI-ERIC engages its community and partners in more than 24 active EU projects fostering different domains towards genomic medicine including e.g. rare diseases, cancer, neurological disorders, pediatrics, and infectious diseases. Our federated access and analysis platform has not only become a strong asset for major EU initiatives (e.g., EHDS, 1+Mio, GDI, EUCAIM) but helps scientists and clinicians to accelerate diagnostics and therapies discovery & development: BBMRI’s fully GDPR-compliant pipeline enables access to samples and data of over 5.1 Mio. patients facilitated by over 400 biobanks across 32 countries. The data comprise 7,834 distinct OMOP variables with biochemical measurements plus different types of OMICs data including e.g., over 200,000 genomes.

            Conclusions: We will showcase how to access and make use of the richness of BBMRI-ERIC’s resources and how to collaborate with our wider community on different topics through in-house or EU funding – locally, nationally or EU wide to foster diagnostics discovery and development of new therapies.

            Content

            Author and article information

            Conference
            RExPO24 Conference
            REPO4EU
            24 May 2024
            Affiliations
            [1 ] BBMRI-ERIC, Graz, Austria;
            Author notes
            Author information
            https://orcid.org/0009-0005-5204-7593
            https://orcid.org/0000-0003-4537-8691
            https://orcid.org/0000-0001-5914-6563
            https://orcid.org/0000-0001-6932-0473
            https://orcid.org/0009-0005-3070-3115
            https://orcid.org/0000-0001-8756-7998
            https://orcid.org/0000-0002-6334-2548
            Article
            10.58647/REXPO.24000067.v1
            61a54f6e-7383-4b1a-9bec-8420e5106bca

            This work has been published open access under Creative Commons Attribution License CC BY 4.0 , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at www.scienceopen.com .

            RExPO24
            3
            Munich, Germany
            3-5 July 2024
            History
            : 24 May 2024
            Product

            REPO4EU

            Categories

            The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
            Life sciences
            BBMRI-ERIC,European research infrastructure,biobanking,biomolecular resources,European Commission,personalized medicine,GDPR,EU Projects,federated access and analysis platform,data

            Comments

            Comment on this article